Could a Vitamin-Like pill protect the brains of people with down syndrome?

NCT ID NCT07278492

Not yet recruiting Disease control Sponsor: Brigham and Women's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 23, 2026 · Updated 3 times

Summary

This early-stage trial tests a supplement called MIB-626 (a form of NMN) in 24 adults with Down syndrome. The goal is to see if it is safe and can raise NAD+ levels, which may help protect against Alzheimer's disease. Participants take the pill or a placebo for 28 days and are monitored for side effects and changes in brain chemistry.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MIB-626 (a form of nicotinamide mononucleotide, or NMN)
What this could lead to: If safe and well-tolerated, this could point toward a way to slow or prevent Alzheimer's disease in people with Down syndrome.
What could go wrong: This is a very early, small Phase 1 trial focused on safety, not effectiveness. It may not show any benefit, and results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DOWN SYNDROME (DS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Down syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DOWN SYNDROME (DS)

Contacts and locations

Locations

Brigham and Women's Hospital

Boston, Massachusetts, 02115, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.